Prior Acne Predicts Breakouts With JAK Inhibitors in AA
Younger patients with alopecia areata (AA) and those who have a history of acne were more likely to develop acne during Janus kinase inhibitor (JAKi) treatment in a study. METHODOLOGY: Researchers conducted a retrospective review of an institutional AA registry and analyzed 54 patients ages 12-78 years (53.7% women; average age, 38.8 years) with AA who received JAKi treatment.
They reviewed demographics, medical history, alopecia history, acne history, current acne, and JAKi use.
The JAKis used were baricitinib (n = 18), deuruxolitinib (n = 17), ritlecitinib (n = 17), upadacitinib (n = 1), and tofacitinib (n = 1). TAKEAWAY: Of all patients, 29 developed acne and 25 did not. Among those with acne, 16 (55%) had mild, nine (31%) had moderate, and four (14%) had severe disease. Overall, 32 (59.3%) patients had a history of acne, including 24 (83%) of the 29 who developed acne during JAKi treatment.
Patients with prior acne history showed a significantly higher likelihood of developing acne during JAKi treatment (odds ratio [OR], 5.95; P = .027). Patients with acne on JAKi were also younger than those without acne (average, 33.6 vs 44.9 years; P = .0097).
= .027). Patients with acne on JAKi were also younger than those without acne (average, 33.6 vs 44.9 years; = .0097). Acne onset typically occurred early in treatment, with 23 (79%) patients developing acne within 3 months; 17 (59%) experienced relapsing/remitting disease. Acne completely resolved in five (17%) patients.
Most patients reported the same (54%) or worse acne severity (29%) after treatment initiation compared with previous acne severity.
Among patients who developed acne, 62% pursued treatment options, with 67% reporting some improvement, while only 3% discontinued JAKi due to acne. IN PRACTICE:
'Younger patients and those with acne history are especially prone to acne on JAKi with similar severity to prior acne,' the study authors wrote. 'Dermatologists should investigate patient acne history prior to JAKi initiation,' they added, and those with a history 'should be counseled on risk of new-onset acne and informed that JAKi-associated acne has moderate responsiveness to conventional therapies.' SOURCE:
The study was led by Emily R. Gordon, Columbia University Vagelos College of Physicians and Surgeons, New York City, and was published online on April 29 in JAAD International . LIMITATIONS:
The study was limited by reliance on patient recall and self-assessment of acne severity. DISCLOSURES:
The authors reported having no funding source or relevant conflict of interests.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Credit
Lead image: E+/Getty Images
Medscape Medical News © 2025 WebMD, LLC
Cite this: Prior Acne Predicts Breakouts With JAK Inhibitors in AA - Medscape - May 12, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Deadline for spring COVID-19 booster approaching - who can get it
The NHS in West Yorkshire has encouraged eligible individuals to get a COVID-19 booster before the current vaccination campaign ends on Tuesday, June 17. The booster is being offered to people aged 75 and over, residents in care homes for older adults, and anyone aged six months and over with a weakened immune system. A spokesperson said: "This includes people who have or are receiving treatment for conditions such as diabetes, blood cancer, organ transplant, HIV, or those taking medicines that weaken the immune system, such as high-dose steroids or immunosuppressants following cancer treatment." Dr James Thomas, medical director for the West Yorkshire Integrated Care Board and a Leeds-based GP, said: "Vaccination remains the best way to protect yourself and those around you from the serious effects of COVID-19. "The virus hasn't gone away, and those most at risk can still become seriously unwell. "If you're eligible for the spring booster, please don't miss this opportunity – book now or visit a walk-in pharmacy before June 17." Appointments can be booked through the NHS App, online at or by calling 119. Some walk-in pharmacies are also available across West Yorkshire. A full definition of immunosuppression can be found in Chapter 14a (table 3) of the Green Book:
Health Line
25 minutes ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
Screen Geek
25 minutes ago
- Screen Geek
2025 Box Office Bomb Dominates HBO Max
Subscribers on HBO Max are flocking to one of 2025's box office bombs as the film unexpectedly tops the streaming service's charts. Of course, it's not surprising that this 2025 effort is doing so well on HBO Max following its theatrical release, especially when one considers that it comes from an acclaimed director. As noted via FlixPatrol, at the time of this writing, this film is the #2 title on the streaming platform. It's quite a feat for a movie that struggled at the box office, having earned just barely more than its budget at the box office, grossing $132 million against a $118 million production cost. Impressively, the title stars Robert Pattinson as the lead, with Naomi Ackie, Steven Yeun, Toni Collette, and Mark Ruffalo. Bong Joon Ho both wrote and directed the film which was based on a novel by Edward Ashton. It seems as though the talent from everyone involved has given this title legs beyond its theatrical release. This 2025 film now streaming on HBO Max is none other than Mickey 17 , a sci-fi film set in the year 2054. It revolves around Pattinson's character who joins a space colony. His official title is that of an 'Expendable,' which is an individual that happens to be cloned upon death. While a majority of their memories are retained, they quickly become diluted with each additional copy. It's an interesting endeavor from Bong Joon Ho, and one that probably should have fared better at the box office. Fortunately, it looks like it has been earning viewers with its newfound availability on HBO Max and home video. Stay tuned to ScreenGeek for any additional updates regarding the latest trending titles on HBO Max as we have them. For now, subscribers are able to see Mickey 17 for themselves, and see whether or not the title was deserving of a better box office performance. Especially now that it appears to be doing quite well on streaming.
